ABHY yields 5.19% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ABHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ABHY + ABBV for your $10,000?
ABHY tracks an index that invests in US-listed high yield ETFs while applying a downside protection. The risk-managed fund employs a tactical strategy that toggles between high yield and US Treasury ETFs. This tactical switch is determined by a daily buy-sell signal. Full exposure is allocated to high yield ETFs when a buy signal is triggered, while 80% is allocated to US Treasurys when it triggers otherwise. Underlying ETFs must meet certain expense ratio and AUM requirements to be considered. In addition, both must have an investment process that excludes factors, hedges and long/short strategies. The underlying ETFs are weighted based on their respective expenses and AUM, whether its junk bonds or Treasurys. The index is rebalanced quarterly and reconstituted annually. DFHYs investors should anticipate frequent trading. Prior to Nov. 29, 2021, the fund was named TrimTabs Donoghue Forlines Tactical High Yield and tracked the TrimTabs Donoghue Forlines Tactical High Yield Index. Prior to Nov. 13, 2024 the fund name was Donoghue Forlines Tactical High Yield ETF and traded under the ticker DFHY.
Full ABHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.